Physician profile
Jennifer E Croft
NPI 1255930426
$4,485.39
in general payments reported to CMS, 2019-2025
50 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $269 · 2022: $159 · 2023: $887 · 2024: $2,065 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,840 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,839.89 |
| Education | $217.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $633.99 | 2023-2025 | Tecentriq, Alecensa, Venclexta |
| Janssen Biotech, INC. | $298.01 | 2023-2025 | Imbruvica, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $244.00 | 2021-2025 | |
| Incyte Corporation | $231.64 | 2023-2025 | Jakafi, Niktimvo |
| Merck Sharp & Dohme LLC | $218.30 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $205.70 | 2021-2025 | Xtandi, Padcev, Vyloy |
| Seagen INC. | $172.83 | 2021-2023 | Tivdak, Tukysa |
| Pfizer INC. | $158.89 | 2021-2025 | |
| Daiichi Sankyo INC. | $152.63 | 2022-2025 | Enhertu, Vanflyta, Injectafer |
| Eisai INC. | $146.89 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $138.70 | 2023-2025 | Imfinzi |
| Genzyme Corporation | $137.24 | 2024-2025 | |
| Celgene Corporation | $126.82 | 2023-2025 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $95.68 | 2024-2025 | Fruzaqla, Ninlaro |
| Lilly USA, LLC | $92.73 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $92.11 | 2023-2025 | Bavencio |
| Genmab U.S., INC. | $90.28 | 2024-2025 | Epkinly |
| Amgen INC. | $89.14 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Blueprint Medicines Corporation | $67.68 | 2024-2025 | Ayvakit |
| Beigene USA, INC. | $65.38 | 2024-2025 | Brukinsa, Tevimbra |
| E.R. Squibb & Sons, L.L.C. | $64.50 | 2022-2025 | Krazati, Opdualag, Opdivo |
| Gilead Sciences, INC. | $59.30 | 2022-2024 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $57.31 | 2023-2024 | Tavalisse, Rezlidhia |
| Karyopharm Therapeutics INC. | $56.54 | 2024-2025 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $56.10 | 2024-2025 | Libtayo |
| Servier Pharmaceuticals LLC | $55.13 | 2024-2025 | |
| Exelixis INC. | $51.64 | 2024-2025 | Cabometyx |
| Tersera Therapeutics LLC | $51.35 | 2024-2025 | Zoladex |
| Myriad Genetic Laboratories, INC. | $51.04 | 2022-2025 | Myrisk |
| Sumitomo Pharma America, INC. | $42.22 | 2024-2025 | Orgovyx |
| Sobi, INC | $39.15 | 2025 | |
| Stemline Therapeutics INC. | $38.89 | 2024-2025 | Orserdu |
| Kite Pharma, INC. | $35.96 | 2024-2025 | Yescarta |
| Azurity Pharmaceuticals, INC. | $35.50 | 2025 | Danziten |
| Ipsen Biopharmaceuticals, INC | $34.97 | 2022-2023 | Somatuline Depot, Onivyde |
| Aveo Pharmaceuticals, INC. | $34.69 | 2024-2025 | |
| Geron Corporation | $33.84 | 2025 | Rytelo |
| Abbvie INC. | $30.12 | 2024 | |
| Amneal Pharmaceuticals LLC | $29.14 | 2023 | Avastin, Neupogen, Neulasta |
| Spectrum Pharmaceuticals INC. | $19.08 | 2024 | Rolvedon |
| Acrotech Biopharma INC. | $18.20 | 2024 | Beleodaq |
| Pharmaand Gmbh | $17.19 | 2025 | Rubraca |
| Tolmar, INC. | $17.19 | 2025 | Rubraca |
| Heron Therapeutics, INC. | $15.05 | 2023 | Sustol |
| Pharmacyclics LLC, An Abbvie Company | $14.59 | 2023 | Imbruvica |
| Janssen Pharmaceuticals, INC | $13.97 | 2021 | |
| Springworks Therapeutics, INC. | $13.88 | 2024 | Ogsiveo |
| Syndax Pharmaceuticals, INC. | $13.59 | 2025 | |
| Deciphera Pharmaceuticals INC. | $13.54 | 2024 | Qinlock |
| Alnylam Pharmaceuticals INC. | $13.08 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Croft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.